$CAPR
CAPRICOR THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000155837023013763 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $6.186M $3.917M $0.00
YoY Change 288.66% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.020M $2.847M $2.357M
YoY Change 17.74% 20.82% 31.66%
% of Gross Profit
Research & Development $10.00M $8.800M $5.000M
YoY Change 81.82% 76.0% 42.86%
% of Gross Profit
Depreciation & Amortization $276.5K $254.7K $112.0K
YoY Change 101.76% 127.39% 114.05%
% of Gross Profit
Operating Expenses $13.05M $11.66M $7.322M
YoY Change 61.73% 59.32% 38.48%
Operating Profit -$6.865M -$7.747M -$7.322M
YoY Change 5.97% 5.81% 44.04%
Interest Expense $480.0K $380.7K $21.76K
YoY Change 350.11% 1649.45% 29.99%
% of Operating Profit
Other Income/Expense, Net $474.0K $380.7K $212.3K
YoY Change 344.5% 79.28% -36.6%
Pretax Income -$6.390M -$7.367M -$7.109M
YoY Change 0.3% 3.62% 49.73%
Income Tax
% Of Pretax Income
Net Earnings -$6.391M -$7.367M -$7.109M
YoY Change 0.31% 3.62% 49.73%
Net Earnings / Revenue -103.31% -188.04%
Basic Earnings Per Share -$0.25 -$0.29 -$0.29
Diluted Earnings Per Share -$0.25 -$0.29 -$0.29
COMMON SHARES
Basic Shares Outstanding 25.78M 25.27M 24.32M
Diluted Shares Outstanding 25.82M 25.34M 24.32M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.52M $37.79M $51.42M
YoY Change -38.82% -26.5% 35.03%
Cash & Equivalents $8.985M $9.837M $16.39M
Short-Term Investments $19.54M $27.96M $35.02M
Other Short-Term Assets $460.0K $583.8K $659.3K
YoY Change 33.85% -11.44% 0.91%
Inventory
Prepaid Expenses
Receivables $550.0K $547.6K $547.6K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $29.53M $38.92M $52.62M
YoY Change -37.84% -26.03% 35.87%
LONG-TERM ASSETS
Property, Plant & Equipment $5.140M $4.790M $2.629M
YoY Change 43.11% 82.18% 136.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K $268.2K $268.2K
YoY Change 0.68% 0.0% 202.33%
Total Long-Term Assets $7.625M $7.086M $5.442M
YoY Change 18.71% 30.22% 353.95%
TOTAL ASSETS
Total Short-Term Assets $29.53M $38.92M $52.62M
Total Long-Term Assets $7.625M $7.086M $5.442M
Total Assets $37.15M $46.01M $58.07M
YoY Change -31.11% -20.76% 45.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.790M $5.134M $3.222M
YoY Change 72.49% 59.34% 1.52%
Accrued Expenses $730.0K $707.4K $579.7K
YoY Change 4.65% 22.04%
Deferred Revenue $25.41M $29.31M $15.70M
YoY Change 36.59% 86.7%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.93M $35.15M $19.55M
YoY Change 41.96% 79.84% 515.92%
LONG-TERM LIABILITIES
Long-Term Debt $3.380M $3.376M $3.376M
YoY Change 0.11% 0.0% 0.0%
Other Long-Term Liabilities $2.640M $4.750M $16.41M
YoY Change -77.87% -71.06%
Total Long-Term Liabilities $6.013M $8.126M $19.79M
YoY Change -60.72% -58.94% 486.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.93M $35.15M $19.55M
Total Long-Term Liabilities $6.013M $8.126M $19.79M
Total Liabilities $38.94M $43.28M $39.34M
YoY Change 1.14% 10.02% 500.57%
SHAREHOLDERS EQUITY
Retained Earnings -$158.6M -$152.2M -$123.0M
YoY Change 22.61% 23.76% 25.58%
Common Stock $156.7M $154.8M $141.7M
YoY Change 8.32% 9.23% 7.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.788M $2.731M $18.73M
YoY Change
Total Liabilities & Shareholders Equity $37.15M $46.01M $58.07M
YoY Change -31.11% -20.76% 45.42%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$6.391M -$7.367M -$7.109M
YoY Change 0.31% 3.62% 49.73%
Depreciation, Depletion And Amortization $276.5K $254.7K $112.0K
YoY Change 101.76% 127.39% 114.05%
Cash From Operating Activities -$8.790M -$9.418M -$6.542M
YoY Change 54.6% 43.95% 44.94%
INVESTING ACTIVITIES
Capital Expenditures $630.0K $233.4K -$412.6K
YoY Change -157.31% -156.58% 29.18%
Acquisitions
YoY Change
Other Investing Activities $8.350M $6.695M -$35.00M
YoY Change -371.34% -119.13%
Cash From Investing Activities $7.720M $6.461M -$35.41M
YoY Change -284.84% -118.25% 10988.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.0K 2.188M 15.00K
YoY Change -88.31% 14487.13% -98.55%
NET CHANGE
Cash From Operating Activities -8.790M -9.418M -6.542M
Cash From Investing Activities 7.720M 6.461M -35.41M
Cash From Financing Activities 220.0K 2.188M 15.00K
Net Change In Cash -850.0K -768.4K -41.94M
YoY Change -89.35% -98.17% 1004.29%
FREE CASH FLOW
Cash From Operating Activities -$8.790M -$9.418M -$6.542M
Capital Expenditures $630.0K $233.4K -$412.6K
Free Cash Flow -$9.420M -$9.651M -$6.130M
YoY Change 105.39% 57.45% 46.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25335342
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24324156
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25291591
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24303564
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42471
dei Entity Central Index Key
EntityCentralIndexKey
0001133869
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25241402
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25764312
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25764312
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34058
dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
727-1755
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CAPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25776867
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9837133
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9603242
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27956325
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
31818020
CY2023Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
583835
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
919892
CY2023Q2 us-gaap Assets Current
AssetsCurrent
38924873
CY2022Q4 us-gaap Assets Current
AssetsCurrent
42888734
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4789786
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2028367
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2349974
CY2023Q2 us-gaap Other Assets
OtherAssets
268172
CY2022Q4 us-gaap Other Assets
OtherAssets
268172
CY2023Q2 us-gaap Assets
Assets
46011198
CY2022Q4 us-gaap Assets
Assets
50094910
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5115182
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4834683
CY2023Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
18628
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
89234
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
707425
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
682039
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
29312439
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17980599
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35153674
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23586555
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1518173
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1878070
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3231929
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9467932
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8126361
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14722261
CY2023Q2 us-gaap Liabilities
Liabilities
43280035
CY2022Q4 us-gaap Liabilities
Liabilities
38308816
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25764312
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25241402
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
25764
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25241
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
154740362
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148735420
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
179693
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
105244
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152214656
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137079811
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2731163
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46011198
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50094910
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3917467
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6904163
CY2023Q2 us-gaap Revenues
Revenues
3917467
us-gaap Revenues
Revenues
6904163
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8817389
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4965088
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16478908
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10080787
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2847337
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2356666
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6357222
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5072501
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11664726
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
7321754
us-gaap Operating Expenses
OperatingExpenses
22836130
us-gaap Operating Expenses
OperatingExpenses
15153288
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7747259
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7321754
us-gaap Operating Income Loss
OperatingIncomeLoss
-15931967
us-gaap Operating Income Loss
OperatingIncomeLoss
-15153288
CY2022Q2 us-gaap Other Income
OtherIncome
190582
us-gaap Other Income
OtherIncome
190582
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
380680
CY2022Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
21761
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
797122
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
35201
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
380680
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
212343
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
797122
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
225783
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7366579
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7109411
us-gaap Net Income Loss
NetIncomeLoss
-15134845
us-gaap Net Income Loss
NetIncomeLoss
-14927505
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74449
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7281872
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7086581
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15060396
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14904675
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25335342
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24324156
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25291591
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24303564
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2194784
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3895
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2130395
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1618712
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57679
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7366579
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2731163
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1065329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27465
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7818094
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
24642666
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1157904
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15006
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7109411
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18728995
us-gaap Profit Loss
ProfitLoss
-15134845
us-gaap Profit Loss
ProfitLoss
-14927505
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
484803
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
204501
us-gaap Share Based Compensation
ShareBasedCompensation
3813496
us-gaap Share Based Compensation
ShareBasedCompensation
2223233
capr Noncash Lease Expenses
NoncashLeaseExpenses
-12904
capr Noncash Lease Expenses
NoncashLeaseExpenses
145466
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
155830
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-336057
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-500668
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7550
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
280499
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11465
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-70607
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-505253
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5095837
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5207664
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
17504295
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52863856
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49012053
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
56800000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14012000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
483563
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
748575
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
202995
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
289345
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3249586
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36037973
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2130395
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61574
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
42471
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2191969
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
233891
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18491207
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9837133
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16394067
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
37800000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
41400000
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023Q2 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
547580
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2023Q2 us-gaap Depreciation
Depreciation
254702
CY2022Q2 us-gaap Depreciation
Depreciation
112011
us-gaap Depreciation
Depreciation
484803
us-gaap Depreciation
Depreciation
204501
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6437934
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5769655
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1648148
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1181625
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4789786
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
capr Grant Income
GrantIncome
0
CY2022Q2 capr Grant Income
GrantIncome
0
capr Grant Income
GrantIncome
0
CY2023Q2 capr Grant Income
GrantIncome
0
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8800000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000000.0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10100000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7300000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7784934
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7784934
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6142203
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6142203
CY2023Q2 capr Amortized Cost Of Marketable Securities
AmortizedCostOfMarketableSecurities
27776632
CY2022Q4 capr Amortized Cost Of Marketable Securities
AmortizedCostOfMarketableSecurities
31712777
capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25764312
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2023Q2 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2021Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1815156
capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.16
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.029
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1618712
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1157904
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3813496
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2223233
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2023Q2 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
37500000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
402744
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
765986
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
710259
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
547948
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2426937
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
201339
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2225598
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
707425
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1518173
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2225598
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M13D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0537
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2000000.0
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
18628
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
89234

Files In Submission

Name View Source Status
0001558370-23-013763-index-headers.html Edgar Link pending
0001558370-23-013763-index.html Edgar Link pending
0001558370-23-013763.txt Edgar Link pending
0001558370-23-013763-xbrl.zip Edgar Link pending
capr-20230630.xsd Edgar Link pending
capr-20230630x10q.htm Edgar Link pending
capr-20230630xex31d1.htm Edgar Link pending
capr-20230630xex31d2.htm Edgar Link pending
capr-20230630xex32d1.htm Edgar Link pending
capr-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
capr-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20230630_pre.xml Edgar Link unprocessable
capr-20230630x10q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
capr-20230630_lab.xml Edgar Link unprocessable
capr-20230630_def.xml Edgar Link unprocessable